Sponsor content
45 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Filsuvez is approved for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FILSUVEZ birch bark dry extract (84-95% triterpenes) 100 mg/g gel tube.
-
Prescription medicine decision summaryFilsuvez (Birch bark dry extract - 84-95% triterpenes) has been approved for the treatment of partial-thickness wounds of the skin associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
-
Prescription medicine registrationActive ingredients: birch bark dry extract (84-95 per cent) triterpenes.
-
Australian public assessment report (AusPar)Elfabrio (pegunigalsidase alfa) has been approved for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.
-
Mar-2026Prescription medicine evaluationActive ingredient: idebenone.
-
-
Australian public assessment report (AusPar)Lamzede (velmanase alfa) has been approved as an enzyme replacement therapy for the treatment of non-central nervous system manifestations in patients with alpha-mannosidosis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELFABRIO pegunigalsidase alfa 20 mg/10 mL concentrated injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAMZEDE velmanase alfa 10 mg powder for injection vial.